Krsnaa Diagnostics Board Approves Q1 FY27 Results, Declares ₹2 Dividend, Issues Warrants
Krsnaa Diagnostics approved Q1 FY27 results with consolidated revenue of ₹2,355.32 crore and profit after tax of ₹65.51 crore. A final dividend of ₹2.00 per share was recommended. The company will issue 16,21,000 warrants to promoters at a price higher than ₹565. The 16th AGM is on September 28, 2026.
The issuance of warrants to promoters and the declaration of a dividend are significant corporate actions that can impact the company's capital structure and shareholder returns.
The company reported financial results, recommended a dividend, and approved the issuance of warrants to promoters, indicating positive corporate actions and financial performance.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on August 13, 2026. The Board approved the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026, along with the Limited Review Reports.
Additionally, the Board approved the Director's Report for the financial year 2025-26 and the Notice for the 16th Annual General Meeting (AGM) scheduled for Monday, September 28, 2026, at 11:00 Hrs. (IST) through physical mode. The record date for the final dividend payment is set for Friday, September 18, 2026, with book closure from Saturday, September 19, 2026, to Monday, September 28, 2026. A final dividend of ₹2.00 per share for FY 2024-25 was recommended by the Board.
Furthermore, the company approved the issuance of 16,21,000 share warrants to promoter entities, Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited. The issue price will be determined in the future, at a rate higher than ₹565 or the floor price as per SEBI regulations. Each warrant is convertible into one equity share of face value ₹5, exercisable within 18 months of allotment. The Board Meeting commenced at 13:30 Hrs. (IST) and concluded at 21:00 Hrs. (IST). The company also reported consolidated revenue from operations of ₹2,355.32 crore for the quarter ended June 30, 2026, and a profit after tax of ₹65.51 crore. Standalone revenue from operations was ₹2,106.61 crore, with a profit after tax of ₹58.20 crore for the same period.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.